CD274 and nonpapillary renal cell carcinoma: According to the evidence that tumors with higher TMB implied better ICI efficacy (32), we speculated that the high-risk group with higher genomic alteration burden possessed a better response to anti-PD-1 or anti-PD-L1 antibody treatment in ccRCC.